Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advances and challenges in hereditary cancer pharmacogenetics.

Expert opinion on drug metabolism & toxicology - 1 Jan 2017

Cascorbi Ingolf, Werk Anneke Nina

Abstract excerpt

INTRODUCTION: Cancer pharmacogenetics usually considers tumor-specific targets. However, hereditary genetic variants may interfere with the pharmacokinetics of antimetabolites and other anti-cancer drugs, which may lead to severe adverse events. Areas covered: Here, the impact of hereditary genes considered in drug labels such as thiopurine S-methyltransferase (TPMT), UDP-glucuronosyltransferase 1A1 (UTG1A1) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Genetic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Membrane Transport Proteins

Share to Neoplasms

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Treatment Outcome

Source

Identifiers

PMID: 27603572
DOI: 10.1080/17425255.2017.1233965

Genes

DPYD
TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advances and challenges in hereditary cancer pharmacogenetics.PMID 27603572Read ↗

Germline oncopharmacogenetics, a promising field in cancer therapy.Semantic proximity Read ↗

TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase.Semantic proximity Read ↗

Pharmacogenomic discovery approaches: will the real genes please stand up?Semantic proximity Read ↗

Modern developments in germline pharmacogenomics for oncology prescribingSemantic proximity Read ↗

Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.Semantic proximity Read ↗

Inherited variations in drug-metabolizing enzymes: significance in clinical oncology.Semantic proximity Read ↗

Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.Semantic proximity Read ↗

Germline genetic testing to predict drug response and toxicity in oncology--reality or fiction?Semantic proximity Read ↗

Genetic polymorphisms of drug metabolizing enzymes and transporters: the long way from bench to bedside.Semantic proximity Read ↗

Application of pharmacogenetics in oncologySemantic proximity Read ↗

[Pharmacogenetics of anticancer drugs].Semantic proximity Read ↗

Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.